Abstract
Medically ill patients present with a high prevalence of non-specific comorbid symptoms including pain, sleep disorders, fatigue and cognitive and mood alterations that is a leading cause of disability. However, despite major advances in the understanding of the immune-to-brain communication pathways that underlie the pathophysiology of these symptoms in inflammatory conditions, little has been done to translate this newly acquired knowledge to the clinics and to identify appropriate therapies. In a multidisciplinary effort to address this problem, clinicians and basic scientists with expertise in areas of inflammation, psychiatry, neurosciences and psychoneuroimmunology were brought together in a specialized meeting organized in Bordeaux, France, on May 28-29, 2007. These experts considered key questions in the field, in particular those related to identification and quantification of the predominant symptoms associated with inflammation, definition of systemic and central markers of inflammation, possible domains of intervention for controlling inflammation-associated symptoms, and relevance of animal models of inflammation-associated symptoms. This resulted in a number of recommendations that should improve the recognition and management of inflammation-associated symptoms in medically ill patients.
Original language | English |
---|---|
Pages (from-to) | 18-29 |
Number of pages | 12 |
Journal | Psychoneuroendocrinology |
Volume | 33 |
Issue number | 1 |
DOIs | |
State | Published - Jan 2008 |
Bibliographical note
Funding Information:Some of the studies reported in this paper were supported by NIH grants to RD, AHM, and MRI.
Keywords
- Acute phase protein
- Animal models
- Biologic marker
- Brain
- Depression
- Fatigue
- Inflammation
- Neuroimaging
- Proinflammatory cytokines
- Symptom burden
- Therapy